The Art of Investing Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : The Art of Investing

PICK 51.06

+2.3%

Dec 22 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Sun Tzu

10/30/2025 7:42:03 PM

Read Replies (1) of 10712

TVTX - Travere Therapeutics' Q3 revenue surges on FILSPARI growth
Oct 30, 2025, 17:01 GMT-4RefinitivLess than 1 min read

TVTX-1.10%
Overview

Travere Q3 2025 total revenue rose to $164.9 mln, driven by FILSPARI sales growth
FILSPARI U.S. net product sales grew 155% yr/yr to $90.9 mln in Q3 2025
Travere achieved $25.7 mln net income in Q3 2025, reversing a loss from prior year

Outlook

Travere expects FDA approval for FILSPARI in FSGS by January 2026
Travere aims to restart HARMONY Study of pegtibatinase in 2026

Result Drivers

FILSPARI SALES GROWTH - FILSPARI U.S. net product sales increased 155% yr/yr to $90.9 mln, driven by continued uptake among prescribers
MARKET ACCESS MILESTONE - $40 mln market access milestone from CSL Vifor recognized in Q3 2025, enhancing financial results

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q3 Product Sales		$113.15 mln
Q3 EPS		$0.28
Q3 Net Income		$25.70 mln
Q3 Operating Expenses		$139.92 mln
Q3 Operating Income		$24.93 mln

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Travere Therapeutics Inc is $35.00, about 14.3% above its October 29 closing price of $29.98

Press Release:

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next